This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Onconova Therapeutics To Host Analyst Event In New York City On December 19th

NEWTOWN, Pa., Dec. 13, 2013 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, will be hosting an investor and analyst event on Thursday, December 19, 2013, from 8:00 am to 12:00 pm ET in New York, NY. The meeting will focus on the treatment landscape of myelodysplastic syndromes (MDS) and the development of Onconova's most advanced product candidate, rigosertib, as a novel treatment for MDS and other cancers. The event will feature presentations by leading experts in the fields of oncology and hematology and Onconova management.

Experts will include:
  • Jerome Groopman, M.D., the Dina and Raphael Recanati Chair of Medicine at Harvard Medical School and Chief of Experimental Medicine at Beth Israel Deaconess Medical Center  
  • James F. Holland, M.D., Distinguished Professor of Neoplastic Diseases at the Icahn School of Medicine at Mount Sinai; Lasker Award winner for contributions to the cure of childhood leukemias  
  • Jimmie C. Holland, M.D., Wayne E. Chapman Chair in Psychiatric Oncology at Memorial Sloan-Kettering Cancer Center; pioneer in assessing quality of life measures in clinical trials  
  • Azra Raza, M.D., Director of the MDS Center at Columbia University  
  • E. Premkumar Reddy, Ph.D., Professor of Oncological Sciences and Structural and Chemical Biology at the Icahn School of Medicine at Mount Sinai; Scientific Founder of Onconova  
  • Lewis R. Silverman, M.D., Associate Professor Medicine, Hematology and Medical Oncology and Assistant Professor Oncological Sciences at the Icahn School of Medicine at Mount Sinai  
  • Alan Williamson, Ph.D., Chairman of the Onconova Therapeutics Clinical Advisory Board

The event is open to members of the professional investment community. For more information on attending please contact Michaela Parnell at

The event audio and slide presentation will be webcast live on the Company's website, , on the Events & Presentations page under the Investors and Media tab.

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are in clinical trials, and several candidates are in pre-clinical stages. For more information, please visit
CONTACT: Onconova Therapeutics
         Benjamin Hoffman, 267-759-3680


         MacDougall Biomedical Communications
         Chris Erdman, 781-235-3060

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 0.00%
FB $117.81 0.00%
GOOG $701.43 0.00%
TSLA $211.53 0.00%
YHOO $36.94 0.00%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs